rs17879961 — CHEK2 I157T

Every time one of your cells divides, its entire genome must be copied with near-perfect fidelity. When copying errors create double-strand DNA breaks, a surveillance network activates to halt the cell cycle until repairs are complete. CHEK2 (checkpoint kinase 2) is a critical node in this network — it receives the damage signal from ATM¹¹ ATM
Ataxia telangiectasia mutated — the upstream kinase that detects double-strand breaks and phosphorylates CHEK2 to initiate cell cycle arrest and relays it to effectors including p53, BRCA1, and CDC25 phosphatases. The I157T variant doesn't destroy CHEK2's enzymatic machinery — it subtly corrupts the sensor domain that activates the protein in the first place, leaving a partially dysfunctional checkpoint that allows more damaged cells to escape surveillance and potentially become cancerous.

CHEK2 activates through a two-step process. First, ATM phosphorylates CHEK2 on threonine 68 in the SQ/TQ cluster domain. This phosphorylation is recognized by the FHA domain²² FHA domain
Forkhead-associated domain — a phosphopeptide-binding module that mediates protein-protein interactions through recognition of phosphothreonine residues; found in many DNA damage checkpoint proteins of a second CHEK2 molecule, driving homodimerization. The homodimer then undergoes autophosphorylation within the kinase domain, fully activating CHEK2 and releasing active monomers to phosphorylate downstream targets.

Isoleucine 157 sits at the center of the FHA domain's phosphopeptide-binding cleft. The I157T substitution replaces a nonpolar isoleucine with a polar threonine, disrupting van der Waals contacts at the FHA-kinase domain interface and reducing the affinity of the domain for phosphorylated binding partners. The result is a protein with essentially normal kinase activity in isolation but impaired activation — the I157T protein cannot efficiently dimerize in response to DNA damage signals, and in vitro studies³³ in vitro studies
Kilpivaara et al. Int J Cancer, 2004 confirm that it underperforms in substrate recognition and fails to mount a full response to ionizing radiation.

There is also a dominant-negative concern: CHEK2 operates as a homodimer. I157T protein can form heterodimers with wild-type CHEK2, potentially sequestering functional protein in non-productive complexes and reducing effective checkpoint activity below what would be expected from simple haploinsufficiency.

Unlike the CHEK2 1100delC frameshift (rs555607708), which destroys the kinase domain entirely and is unambiguously pathogenic, I157T is a partial loss-of-function variant. Its effects on cancer risk are real but smaller — this distinction has important implications for clinical management.

The variant was first associated with breast cancer⁴⁴ first associated with breast cancer
Kilpivaara O et al. CHEK2 variant I157T may be associated with increased breast cancer risk. Int J Cancer, 2004 in a Finnish and Polish case-control study, finding I157T in 7.4% of breast cancer patients versus 5.3% of controls (OR 1.43, 95% CI 1.06–1.95). This study also provided the first functional evidence that I157T impairs the cellular response to ionizing radiation.

A comprehensive meta-analysis⁵⁵ comprehensive meta-analysis
Han FF et al. The effect of CHEK2 variant I157T on cancer susceptibility: evidence from a meta-analysis. DNA Cell Biol, 2013 pooling 18 case-control studies (26,336 cases and 44,219 controls) quantified the risk: OR 1.58 (95% CI 1.42–1.75) for breast cancer and OR 1.67 (95% CI 1.24–2.26) for colorectal cancer. Familial cases showed stronger associations (OR 1.85, 95% CI 1.51–2.26), consistent with a modifier gene acting on a background of other cancer-predisposing variants.

For colorectal cancer specifically, a systematic review⁶⁶ systematic review
Liu C et al. The CHEK2 I157T variant and colorectal cancer susceptibility: a systematic review and meta-analysis. Asian Pac J Cancer Prev, 2012 analyzing 4,029 cases and 13,844 controls found OR 1.61 for unselected colorectal cancer, rising to OR 1.97 for familial colorectal cancer cases.

Thyroid cancer is a notable I157T-enriched cancer type. A Polish study⁷⁷ Polish study
Siołek M et al. CHEK2 mutations and the risk of papillary thyroid cancer. Int J Cancer, 2015 found I157T in 13.3% of papillary thyroid cancer patients versus 6% of controls (OR 2.8). A separate Great Poland cohort⁸⁸ Great Poland cohort
Przybylska-Felus M et al. c.470T>C CHEK2 missense variant increases the risk of differentiated thyroid carcinoma. Hered Cancer Clin Pract, 2015 confirmed a 2.7-fold increased thyroid cancer risk for I157T carriers, making thyroid the cancer type with one of the clearest I157T associations outside breast and colorectal cancer.

A particularly striking finding is the I157T association with adult-type ovarian granulosa cell tumors⁹⁹ adult-type ovarian granulosa cell tumors
Švadjlenka et al. CHEK2 p.I157T mutation is associated with increased risk of adult-type ovarian granulosa cell tumors. Cancers, 2022 — a rare ovarian cancer subtype. Among women with CHEK2 mutations, 36% of ovarian cancers were granulosa cell tumors (versus 1.3% in the general population), with a prevalence ratio of 26.5 for I157T specifically. This tumor type typically presents with abnormal uterine bleeding or abdominal symptoms, and the I157T association justifies awareness of this diagnosis in female carriers.

An interesting exception is lung cancer: a genome-wide study¹⁰¹⁰ genome-wide study
Wang Y et al. Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer. Nat Genet, 2014 found that CHEK2 I157T is associated with a reduced risk of squamous lung cancer (OR 0.38, p = 1.27×10⁻¹³). The mechanism for this protective effect is unclear — it may relate to differential CHEK2 function in squamous lung epithelial cells or to population structure effects — but it has been replicated and is one of the few genetically documented protective effects in cancer epidemiology.

Unlike the more severe CHEK2 1100delC frameshift, the I157T variant does not universally trigger high-risk surveillance protocols in isolation. Current NCCN and ACMG guidance (2024) indicates that I157T alone, without additional family history burden, does not meet the threshold for enhanced breast cancer screening beyond age-appropriate population guidelines. However, when family history includes first-degree relatives with breast, colorectal, thyroid, or prostate cancer, risk management should be personalized accordingly.

The most actionable implications of I157T are: (1) awareness of the multi-organ nature of the risk elevation — this is not just a breast cancer variant; (2) awareness that thyroid cancer risk appears consistently elevated across studies and annual neck palpation or thyroid ultrasound is a low-risk intervention; (3) standard colonoscopy surveillance beginning at age 45 is appropriate and, with a positive family history, consideration of earlier initiation at 40.

CHEK2 I157T operates in the same ATM→CHEK2→p53/BRCA1 checkpoint pathway as multiple other cancer-risk variants in the GeneOps database. CHEK2 is directly phosphorylated and activated by ATM (rs1801516, D1853N), so carriers of both I157T and ATM D1853N may have compounded attenuation of the DNA damage checkpoint. CHEK2 phosphorylates and stabilizes p53 (rs1042522, Pro72Arg affects p53 apoptotic function), so the combination of reduced CHEK2 signaling and a less-activating p53 variant could further elevate risk.

The other major CHEK2 variant in GeneOps, rs555607708 (1100delC), is a far more severe loss-of-function. Compound heterozygosity with 1100delC and I157T is theoretically possible but would be rare; functional data suggest that 1100delC's dominant effect would overshadow I157T's more modest impairment.